---
title: "Jinyu Bio-Technology Co., Ltd. (600201.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600201.SH.md"
symbol: "600201.SH"
name: "Jinyu Bio-Technology Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T16:13:22.728Z"
locales:
  - [en](https://longbridge.com/en/quote/600201.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600201.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600201.SH.md)
---

# Jinyu Bio-Technology Co., Ltd. (600201.SH)

## Company Overview

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.jinyu.com.cn](https://www.jinyu.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.40)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 10 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.50% |  |
| Net Profit YoY | 30.54% |  |
| P/B Ratio | 2.82 |  |
| Dividend Ratio | 0.21% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15379202949.22 |  |
| Revenue | 1388629248.92 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.94% | C |
| Profit Margin | 7.49% | B |
| Gross Margin | 53.48% | B |
| Revenue YoY | 10.50% | B |
| Net Profit YoY | 30.54% | B |
| Total Assets YoY | -2.42% | D |
| Net Assets YoY | 2.90% | C |
| Cash Flow Margin | 288.96% | A |
| OCF YoY | 10.50% | B |
| Turnover | 0.21 | D |
| Gearing Ratio | 14.88% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jinyu Bio-Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "10.50%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "30.54%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.82",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.21%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "15379202949.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1388629248.92",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.94%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.49%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "53.48%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "10.50%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.54%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.42%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.90%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "288.96%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "10.50%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.88%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 142.02 | 35/81 | 195.08 | 161.98 | 119.06 |
| PB | 2.71 | 42/81 | 3.11 | 2.46 | 1.81 |
| PS (TTM) | 10.64 | 51/81 | 12.74 | 10.13 | 7.56 |
| Dividend Yield | 0.22% | 36/81 | 0.35% | 0.25% | 0.19% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-24T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.32 |
| Highest Target | 20.70 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600201.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600201.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600201.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600201.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**